Web-Based PrEP Decision Support Tool Achieves Strong Retention in Feasibility Trial
A web-based decision support tool designed to reduce decisional conflict around HIV pre-exposure prophylaxis enrollment and adherence moved through a feasibility randomized controlled trial with encouraging operational results. The study’s most concrete signal was not a clinical efficacy claim but a trial-conduct signal: participants stayed engaged. Follow-up retention reached 92% over 6 months, a level that suggests the study procedures were acceptable and that a larger efficacy trial would not be derailed by avoidable loss to follow-up.
For a behavioral intervention in prevention medicine, that matters. PrEP adoption depends on a chain of decisions that is often fragile at the point of initiation, then again at the point of daily or event-driven adherence. A tool built to support those decisions has to fit into real-world workflow, not merely function in theory. This feasibility work tested whether participants would enroll, accept randomization, remain in follow-up, and tolerate repeated measurement. On those terms, the study met an essential threshold for future development.
The trial also used a direct pharmacologic measure to assess adherence: dried blood spot, or DBS. That choice strengthens the design because self-report can overestimate medication taking, especially in preventive care where motivation, stigma, and social desirability all affect disclosure. DBS offers a biological readout of recent drug exposure over preceding weeks, making it a more credible adherence marker than recollection alone. In a prevention intervention intended to improve adherence behavior, pairing decision support with a biomarker-based endpoint is more informative than relying on perception or attitude alone.
One sentence captures the operational win: the follow-up protocol held.
Why Decision Conflict Matters in PrEP Uptake
Decision conflict sits at the center of PrEP adoption. People considering PrEP often weigh perceived HIV risk, fear of side effects, concerns about daily medication, privacy issues, cost, and uncertainty about whether the preventive benefit justifies the burden of treatment. A web-based decision support tool is meant to structure that uncertainty, reduce ambivalence, and help the user arrive at a more confident choice. In preventive medicine, indecision is not a neutral state. Delayed initiation can leave a patient exposed during a period when protection would have mattered most.
The feasibility trial was designed to test that premise in a controlled setting. Randomization to the intervention or standard care allowed investigators to examine acceptability under conditions that resemble a future definitive trial. That matters because digital decision aids can appear straightforward during development while proving cumbersome once deployed in routine care. Randomization acceptability, retention, and completion of follow-up therefore become part of the intervention’s real clinical footprint, not just administrative details.
The abstract indicates that the preliminary efficacy data included decision conflict and adherence outcomes, but the study was not powered to detect statistically significant changes in clinical endpoints. That constraint is fundamental. A feasibility trial is built to answer whether the machinery of the study works, not whether the intervention has already won on outcomes. Interpreting any early trend toward benefit requires restraint, because small samples can produce unstable estimates and noisy changes in behavioral measures.
Dried Blood Spot Adherence Testing Gives the Trial Biological Credibility
DBS introduces a different kind of rigor into PrEP research. Instead of depending solely on participant recall, it samples what has actually entered the bloodstream over the recent dosing window. In a prevention trial where adherence is the biological bridge between intent and protection, this is a major methodological advantage. It also helps explain why the investigators emphasized acceptability of a direct pharmacologic biomarker. Participants tolerated that measurement approach, which is useful because biomarker collection can fail in practice if it is intrusive, inconvenient, or poorly understood.
The study’s use of a biomarker also reflects a larger clinical reality: behavior change interventions gain credibility when they can be tied to objective exposure data. Decision aids may improve confidence, but confidence alone does not prevent HIV acquisition. The pathway from better choices to lower risk runs through medication initiation and sustained use. Measuring that pathway with DBS gives future trials a way to distinguish a meaningful adherence effect from a purely attitudinal one.
A second sentence stands out: biomarker-based adherence assessment was acceptable.
What the Feasibility Data Do and Do Not Support
The strongest conclusion from this trial is operational, not efficacy-based. Recruitment and retention strategies appear workable, randomization was acceptable, and the follow-up process produced little attrition. Those are the ingredients of a larger study that can plausibly answer whether the tool truly reduces decision conflict and improves PrEP adherence. Without them, a full-scale trial would risk spending resources on a design that participants could not sustain.
At the same time, the study’s limitations are clear from its own framing. As a pilot feasibility trial, it was not powered to detect statistically significant differences in outcomes. That means the preliminary data on decision conflict and adherence should be treated as signal-seeking rather than practice-changing. No responsible clinical reading can elevate feasibility into efficacy. The most defensible interpretation is that the intervention appears ready for more definitive testing, not that it has already proven benefit.
The broader implication is straightforward. Digital decision support for PrEP has practical appeal because it targets a common point of failure in prevention care: uncertainty before initiation and inconsistency after initiation. If a tool can lower decisional conflict and do so in a way that preserves engagement across months of follow-up, it could help move more at-risk patients from contemplation to sustained protection. But that claim still depends on a larger randomized trial with enough power to show whether the behavioral changes translate into better adherence and, ultimately, better prevention performance.
For now, the trial shows that the research model itself is usable. Participants remained engaged, the biomarker strategy worked, and the randomized design was feasible within a prevention setting where uptake and persistence are both fragile. What remains unresolved is the size and durability of any true adherence effect, and whether a web-based aid can reliably change PrEP behavior beyond the controlled environment of a pilot study.